Systemic and Portal Vein Delivery of Human Kallikrein Gene Reduces Blood Pressure in Hypertensive Rats

Publisher Website
Google Scholar
Abstract
There is an inverse correlation between systemic blood pressure and urinary kallikrein levels in humans and hypertensive animal models, suggesting that the tissue kallikrein-kinin system plays an important role in blood pressure regulation. In this study, we explored the potential of human kallikrein gene delivery on blood pressure reduction in spontaneously hypertensive rats (SHR). The human tissue kallikrein gene or cDNA was placed under the control of following promoters: the metallothionein gene metal response-element (MRE-pHK), albumin gene (ALB-pHK), Rous sarcoma virus 3′ long terminal repeat (LTR) (RSV-cHK), and cytomegalovirus (CMV-cHK). A single injection of these kallikrein DNAs results in a significant reduction of blood pressure in SHR, which lasts for 5–6 weeks. Systemic delivery of CMV-cHK, RSV-cHK, and MRE-pHK has a greater effect on blood pressure reduction than ALB-pHK, whereas intraportal vein gene delivery of ALB-pHK is more effective than the other kallikrein DNA constructs. The degree of blood pressure reduction depends on the amount of administered DNA and the age of the animals. Reduction of blood pressure was observed in adult, but not young, SHR. The expression of human tissue kallikrein in rats was identified by an ELISA that is specific for human tissue kallikrein. No antibodies to either human tissue kallikrein or its DNA were detected in rat sera after somatic gene delivery. These results show that somatic gene delivery of human tissue kallikrein causes a lowering effect of systolic blood pressure in genetically hypertensive rats and provide valuable information for kallikrein gene therapy in the treatment of hypertension. Systemic and intraportal vein gene delivery of human tissue kallikrein causes a long duration of blood pressure reduction in spontaneously hypertensive rats. The hypotensive effect produced by a single injection of the naked human kallikrein gene lasts for 6 weeks. The degree and duration of blood pressure reduction depends on the various promoters in the human tissue kallikrein gene constructs, DNA dosage, delivery method, and age of animal. These findings indicate that tissue kallikrein is a powerful modulator of systemic blood pressure and that kallikrein gene therapy may be useful in the treatment of human hypertension.